Pharsight

Lumakras is owned by Amgen Inc.

Lumakras contains Sotorasib.

Lumakras has a total of 3 drug patents out of which 0 drug patents have expired.

Lumakras was authorised for market use on 28 May, 2021.

Lumakras is available in tablet;oral dosage forms.

Lumakras can be used as treatment of adult patients with kras g12c-mutated locally advanced or metastatic non-small cell lung cancer (nsclc), as determined by an fda-approved test, who have received at least one prior systemic therapy.

Drug patent challenges can be filed against Lumakras from May, 2025.

The generics of Lumakras are possible to be released after 11 August, 2040.

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10519146	AMGEN INC	KRAS G12C inhibitors and methods of using the same	May, 2038 (15 years from now)
US11236091	AMGEN INC	Solid state forms	May, 2040 (17 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11426404	AMGEN INC	Dosing of KRAS inhibitor for treatment of cancers	Aug, 2040 (17 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	May 28, 2026
Orphan Drug Exclusivity (ODE)	May 28, 2028

Drugs and Companies using SOTORASIB ingredient

NCE-1 date: May, 2025

Market Authorisation Date: 28 May, 2021

Treatment: Treatment of adult patients with kras g12c-mutated locally advanced or metastatic non-small cell lung cancer (nsclc), as determined by an fda-approved test, who have received at least one prior systemic therapy

Dosage: TABLET;ORAL